<DOC>
	<DOCNO>NCT01021332</DOCNO>
	<brief_summary>Clinical study examine safety , tolerability efficacy long-term combination therapy tamsulosin solifenacin treatment male low urinary tract symptom ( LUTS ) associate benign prostatic hyperplasia ( BPH ) substantial storage component .</brief_summary>
	<brief_title>Long Term Study Solifenacin Succinate Tamsulosin Hydrochloride Oral Controlled Absorption System ( OCAS ) Males With Lower Urinary Tract Symptoms</brief_title>
	<detailed_description>This open-label extension study follow double blind 905-CL-055 study</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Completion 12 week doubleblind treatment Study 905CL055 Any significant PVR volume ( &gt; 150 mL )</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Lower Urinary Tract Symptoms</keyword>
	<keyword>Treatment</keyword>
	<keyword>Solifenacin succinate</keyword>
	<keyword>Tamsulosin hydrochloride OCAS</keyword>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>EC905</keyword>
	<keyword>Vesomni</keyword>
</DOC>